Background: The MAGE and BAGE genes code for distinct antigens, which are recognized on melanoma cells as well as on other various tumor cells by autologous cytolytic T lymphocytes. These antigens may thus constitute useful targets for specific immunotherapy, since no expression of MAGE or BAGE genes has been recognized in normal tissue except for the testis.
Introduction
The MAGE-1 gene, which codes for tumor-rejection antigen, was isolated from a human melanoma cell line named MZ2-MEL [lj.The MAGE-1-encoded nonapeptide combines with HLA-A1 or HLA-Cwl601 to form a tumor antigen which is recognized by autologous cytotoxicT lymphocytes (CTL). Like the MAGE-1 gene, the MAGE-3 gene codes for a tumor specific antigen presented by either HLA-A1 or HLA-A2. The BAGE gene, which was also isolated from the melanoma cell line MZ2-MEL, codes for a tumor specific antigen presented by HLA-Cwl601 [2] . Tumors expressing MAGE and/or BAGE genes are therefore potential targets for cancer specific immunotherapy, because these genes are expressed only in tumor tissue and not in any normal tissue except for the testis and placenta.
The MAGE-1 or MAGE-3 genes are expressed in human tumors in various organs such as lung [3] , breast [4] , bladder [5] , and digestive organs [6] [7] [8] . The tumors expressing MAGE genes have been found to show several characteristic clinicopathologic features. With respect to breast carcinomas, however, little information has been reported on either the expression of MAGE and BAGE genes, or on the relationship between the expression of these genes and the clinico-pathologic characteristics. We herein report our findings on the MAGE and BAGE gene expression in Japanese breast cancers and discuss both the characteristics of tumors with such gene expression as well as the possibility of performing specific immunotherapy in human breast cancers.
5-Aza-2'-deoxycytidine (DAC), a demethylating agent, is capable of inducing MAGE-1 expression in MAGE-1 negative melanoma cell lines [9] . If an upregulation of MAGE or BAGE gene expression can be induced with DAC in breast cancers, the number of potential clinical cases appropriate for specific immunotherapy may thus be increased. We herein also discuss the results of the effect of DAC on the regulation of MAGE and BABE genes in human breast cancer cell lines.
Materials and methods

Cell lines and tissue samples
All cell lines, which derived from breast cancers, were provided by the Japanese Cancer Reseach Resources Bank. The cell lines, such as MRK-nu-1, YMB-1, YMB-l-E and MCF-7, were all maintained in an RPMI medium supplemented with 10% FCS and antibiotics (penicillin and streptomycin) in a 5% CO2 incubator at 37 °C. Tumor samples and matched control samples of normal mammary tissue located far from the tumor site were immediately frozen at -90 °C until the extraction of RNA. The surgical samples were obtained from the Department of Surgery, Oita Prefectural Hospital, Oita, and the Department of Surgery, Medical Institute of Bioregulation, Kyushu University, Beppu, Japan.
Treatment of cells with 5-aza-2'-deoxycytidine
The breast cancer cell lines were maintained in an RPMI medium in a 5% CO 2 incubator at 37 °C, and 1 uM 5-aza-2'-deoxycytidine was added for 48 hours. The cells were harvested and washed with phosphate-buffer saline prior to RNA extraction Assay for MAGE and BAGE gene expression Total RNA was isolated using the AGPC procedure. cDNA was synthesized from 2.5 ug of total RNA as previously described [3, 6] . cDNA was stored at -20 °C until use. The presence of MAGE-1,-3 and BAGE cDNA in the reverse transcription products was investigated by PCR amplification, using oligonucleotide primers located in different exons of the genes [2, 3] . PCR was performed for 33 cycles (1 min at 94 °C, 2 min at 71 °C and 2 min at 72 °C for MAGE-1 and -3; 1 min at 94 °C, 2 min at 62 °C and 2 min at 73 °C for BAGE). As for the PCR product, 5 ul was size-fractionated on a 2% agarose gel and visualized with ethidium bromide staining. To prevent the occurrence of occasional false-positive PCR products due to any genomic DNA contamination, the primers used in the reverse transcription-polymerase chain reaction (RT-PCR) amplification were located m different exons. For each sample, PCR was performed at least three times Next, in order to confirm the specificity of PCR products of MAGE-1, MAGE-3 and BAGE, we cloned the PCR products into pCR™II vector (Invitrogen) and sequenced the cDNA in positive control respectively with the chain-termination DNA sequencing method We determined the nucleotide sequence of this PCR product and confirmed that it was identical to the expected fragment of cDNA of MAGE-1, MAGE-3 and BAGE. The quality of the RNA preparations was tested in each case by PCR amplification of g]yceraldehyde-3-phosphate dehydrogenase (GAPDH) cDNA [10] . The cycling conditions was as follows: 1 min at 94 °C, 2 min at 56 °C and 2 min at 72 °C. The primer sequences for GAPDH were: 5'-GTCAACGGATTTGGTCGTATT-3' and 5'-AGTCTTCTGGGTGGCAGTAGT-3'.
Clinicopathologic data and statistical analysis
All data including the stage of the disease and pathologic factors were obtained from the clinical and pathologic records. The statistical analysis was performed using Fisher's exact test.
Results
Expression of MAGE genes in surgical specimens
Out of 49 mammary carcinoma samples, 15 (31%) expressed MAGE-1, 12 (24%) expressed MAGE-3 and 4 (8%) expressed BAGE genes as determined by RT-PCR (Figure 1 ). The sequence of the PCR products confirmed that the PCR products were those coded by the expected genes. No expression was observed in any of the matched control samples from normal tissue specimens. MAGE-1, MAGE-3 and BAGE are potentially target genes for specific immunotherapy [2, [11] [12] [13] [14] . The expression of either MAGE-1, MAGE-3 or BAGE was observed in 21 (42%) of the tumor.
Several pathologic factors were compared between the cases with or without MAGE and BAGE gene expression. As far as the expression of MAGE-3 is concerned, significant differences were observed regarding the presence of lymphatic and/or vascular vessel permeations between the two groups {P < 0.05) ( Table  1) . However, no significant differences were seen between the cases with MAGE or BAGE gene expressions and those without those gene expressions regarding such factors as lymph node metastasis, disease stage, estrogen receptor, or progesterone receptor.
Induction of MAGE and BAGE genes expression by 5-aza-2'-deoxycytidine
MRK-nu-1 expressed both MAGE-1 and MAGE-3 genes while MCF-7, YMB-1, and YMB-l-E did not express those genes. In contrast, the BAGE gene expression was seen in all four cell lines. MAGE-1 gene expression was induced by DAC in one of the three MAGE-1 negative cell lines. In addition, the MAGE-3 gene expression was induced in one of the three MAGE-3 negative cell lines (Figure 2 ).
Discussion
Several kinds of carcinomas express MAGE or BAGE genes. With respect to the expression rate, the frequency of MAGE-1 gene expression ranged from 3% in renal carcinomas to 62% in esophageal carcinomas [7, 15] , while the MAGE-3 gene expression ranged from 12% in mammary carcinomas to 69% in melanomas [11] . On the other hand, the frequency of BAGE gene expression Figure 2 . Induction of MAGE-1 and -3 genes expression by 5-aza-2'-deoxycytidine (DAC). In each cell line, the left and right lanes show the status before and after treatment with DAC, respectively. YMB-1 shows a weak induction of MAGE-1 after treatment with DAC. YMB-1-E also shows a weak induction of MAGE-3 after treatment with DAC ranged from 0% in colorectal carcinomas to 23% in melanomas [2] .
With respect to human breast cancers, Brasseur et al. analyzed 44 cancers by RT-PCR and reported that nine tumor samples (20%) expressed MAGE-1 [4] . Russo et al. indicated that MAGE genes are expressed in 11% of all primary breast cancers [16] . Our study revealed that 31% of tumor samples expressed the MAGE-1 gene, and 24% expressed the MAGE-3, thus demonstrating a higher expression rate in Japanese than in Europeans. Boel et al. indicated that BAGE gene expression was detected in 8 of 79 tumor samples. Our study revealed that only 8% of the tumor samples expressed the BAGE. All tumor samples expressed the BAGE gene also expressed the MAGE-1 gene. These findings thus suggest that not many but a certain percentage of breast cancers do express one or more tumor rejection antigens.
The tumors with MAGE gene expression have been found to show several interesting clinicopathologic chracteristics. Patard et al. estimated that bladder tumors with MAGE gene expression were often seen in advanced cases rather than early stage cases [5] . Our previous studies on colorectal carcinoma also revealed that MAGE-1, -2 and -3 gene expression was seen more frequently in cases with liver metastasis than in those without liver metastasis [8] . The present study also demonstrated that breast cancers with MAGE-3 gene expression were more frequently seen in cases with lymphatic and/or vascular vessel permeations than in those without such permeations. Russo et al. also demonstrated that MAGE gene expression was seen in more metastatic breast cancer cells. These findings thus suggest that although the genetic change in MAGE gene expression may be an early event in the growth of tumors, its expression does seem to correlate with the development of tumors, such as invasion or metastasis in some types of tumors. Therefore, further study is called for to better elucidate this speculation.
Antigens encoded by MAGE and BAGE can be utilized as targets for specific immunotherapy. Specific immunotherapy can be done in cases with MAGE-1/ HLA-A1 or A2 or Cwl601, MAGE-3/HLA-A2 or B44 [17] , BAGE/HLA-Cwl601 and GAGE/HLA-Cw0601. Individuals with HLA-A1, HLA-Cwl601, or HLACw0601 represent only a very small population in Japan. Therefore, specific immunotherapy regimens against MAGE-1/HLA-A1, MAGE-1 /HLA-Cwl601, BAGE/ HLA-Cwl601 or GAGE/HLA-Cw0601 are limited to only breast cancer patients (< 1%). Although the occurrence of HLA-B44 is slight in Japan (7.4%), the number of HLA-A2 carriers is quite large (42%) [18] , and 24% of Japanese breast cancers express MAGE-3. At present, we therefore estimate that about 10% of all Japanese patients with breast cancers might be potential candidates for specific immunotherapy. Based on these findings, MAGE-3/HLA-A2, MAGE-3/HLA-A1, and MAGE-1/HLA-A1 antigens may thus be useful targets for specific immunotherapy in Caucasians, because 49% are HLA-A2 positive, and 26% are HLA-A1 positive [13] .
To increase the number of candidates who may potentially undergo specific immunotherapy, one possibility is to induce MAGE or BAGE gene expression prior to immunization in patients whose tumor does not express these genes. In order to achieve this purpose, the demethylaion agents can be used. One demetylating agent, 5-aza-2'-deoxycytidine (DAC), has been shown to be capable of inducing MAGE-1 expression in MAGE-1 negative cell lines [9] . Our study of four mammary carcinoma cell lines disclosed that MAGE-1 or -3 gene expression was induced in one of the three MAGE-1 negative cell lines or one of the three MAGE-3 negative cell lines, respectively. In phase I and II trials in Europe, serum concentrations ranging from 0.1 to 1 uM were achieved with only modest toxicity in cancer patients treated with DAC [19] [20] [21] . If induction can be achieved with an acceptable level of toxicity, DAC may thus play an important role in helping to increase the number of candidates who may undergo specific immunotherapy.
